+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biosimulation Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Biosimulation Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Biosimulation Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6084021
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biosimulation Market grew from USD 3.55 billion in 2024 to USD 4.07 billion in 2025. It is expected to continue growing at a CAGR of 14.62%, reaching USD 8.07 billion by 2030.

Biosimulation offers a computational framework that integrates biological, chemical, and pharmacological data to model complex drug behaviors. By translating molecular interactions into predictive simulations, organizations can accelerate decision making across discovery and development phases. This in silico approach reduces reliance on costly and time-consuming laboratory studies, enabling early identification of potential safety or efficacy challenges and guiding resource allocation more strategically. As regulatory authorities increasingly embrace modeling and simulation as evidence in regulatory submissions, biosimulation emerges not merely as a support tool but as a core pillar shaping the future of therapeutic innovation. Grounded in robust algorithms and enriched by growing volumes of real-world evidence, biosimulation stands at the intersection of technology and biology, poised to transform pipelines from concept to clinic. With competition intensifying and pressure to shorten time-to-market rising, industry stakeholders must understand how evolving capabilities redefine research paradigms and investment priorities. This introduction sets the stage for examining the transformative shifts reshaping the biosimulation landscape, as well as the external forces and strategic opportunities that will guide the next phase of growth and differentiation.

Transformative Shifts in the Biosimulation Landscape

The biosimulation landscape is undergoing a series of transformative shifts driven by advancements in artificial intelligence, cloud computing, and systems biology. Machine learning algorithms now automate parameter estimation and optimize model calibration, accelerating the generation of actionable insights. Concurrently, the migration of simulation platforms to cloud-native architectures enhances scalability, enabling researchers to run complex computations on demand without heavy upfront infrastructure costs. Integration of real-world data sources-from electronic health records to wearable device streams-facilitates the construction of adaptive models that evolve with emerging clinical evidence. In parallel, regulatory frameworks in major markets are evolving to accommodate in silico evidence, with agencies issuing guidance that clarifies validation requirements and submission expectations. Collaboration between software providers and contract research organizations is becoming more symbiotic, as integrated service models combine expertise in modeling with end-to-end trial design support. These shifts collectively lower the barriers to entry for smaller biotech firms, while also compelling established players to pursue continuous innovation. As a result, organizations that invest in flexible, interoperable platforms and foster cross-functional partnerships will be best positioned to harness the full potential of biosimulation, ensuring that the next generation of therapies reaches patients more rapidly and safely.

Cumulative Impact of United States Tariffs in 2025

The cumulative impact of the United States tariffs implemented in 2025 has reverberated across the biosimulation ecosystem, affecting both hardware procurement and software licensing. Increased duties on imported high-performance computing equipment have elevated capital expenditures for in-house simulation infrastructures, prompting some organizations to reassess build-versus-buy decisions. Simultaneously, higher costs associated with offshore data center services have accelerated the shift toward domestic cloud providers that offer tariff-exempt solutions, though often at a premium. On the software side, licensing fees for specialized molecular modeling and PBPK platforms have risen as vendors pass through additional import costs for components embedded in their development environments. These pricing pressures have driven demand for subscription-based models, where usage fees can be managed more fluidly and capital outlays deferred. For contract services, the tariffs have contributed to a redistribution of global engagements, with companies increasingly partnering with regional providers in tariff-neutral zones or leveraging in-house teams to mitigate exposure. In this evolving tariff environment, firms that proactively diversify their technology sources, renegotiate vendor contracts, and explore hybrid service-delivery arrangements will gain a competitive edge by maintaining cost efficiency without compromising on simulation capabilities.

Key Segmentation Insights Across Offerings, Models, Applications, and Users

Segmentation analysis reveals that the biosimulation market encompasses two primary categories of offerings: services and software. Within the services segment, contract services providers deliver expertise on a project basis, while in-house services teams offer tailored capabilities that align with organizational roadmaps. On the software front, solutions range from molecular modeling and simulation tools to PBPK and PK/PD modeling environments, alongside specialized toxicity prediction and trial design applications. Delivery models further diversify access, including traditional ownership arrangements that involve perpetual licenses and subscription frameworks that offer scalable, usage-based pricing. In terms of application, the market divides between drug development and drug discovery workflows. Drug development comprises clinical trial design and preclinical testing, the latter spanning ADME/Tox profiling and PK/PD analyses. Drug discovery workflows focus on lead identification and optimization as well as target identification and validation. Finally, the end-user base includes contract research organizations, pharmaceutical and biotechnology companies, regulatory authorities seeking model-informed submissions, and academic or private research institutes advancing basic science. Understanding these intersecting dimensions enables stakeholders to tailor their strategies, whether by prioritizing high-value software modules, optimizing service delivery frameworks, or aligning applications with evolving regulatory expectations.

Key Regional Insights Shaping Global Biosimulation Adoption

Regional dynamics in biosimulation are shaped by differing regulatory climates, R&D investment patterns, and commercialization maturity. In the Americas, robust funding from both government agencies and private investors underpins widespread adoption of advanced modeling platforms, with the United States leading in commercial collaborations between technology providers and life science firms. The Europe, Middle East & Africa region showcases a strong emphasis on harmonized regulatory guidelines, driving cross-border partnerships that leverage shared computational resources and pooled expertise. Emerging clusters in the Middle East are beginning to attract trial design services, supported by government initiatives aimed at diversifying economies. Asia-Pacific demonstrates the fastest growth trajectory, fueled by expansive pharmaceutical manufacturing in China and India, increasing local biotechs, and favorable policies promoting digital health. Japan and South Korea stand out for their national strategies that integrate simulation into drug review processes, reinforcing market demand for both off-the-shelf software suites and bespoke contract services. Each region presents distinct opportunities: the Americas for large-scale commercial deployments, EMEA for regulatory-aligned collaborations, and Asia-Pacific for cost-effective expansion and localization of biosimulation solutions.

Key Company Insights Driving Innovation and Collaboration

The competitive landscape features a blend of specialized modeling vendors, integrated platform providers, and multidisciplinary service organizations. Advanced Chemistry Development, Inc. has distinguished itself through innovative molecular simulation algorithms, while Aitia leverages AI-driven platforms to automate parameter generation. Allucent and Biomed Simulation, Inc. focus on niche toxicity prediction and PK/PD modeling, respectively, deepening their scientific expertise. Larger entities like Cadence Design Systems, Dassault Systèmes SE, and Thermo Fisher Scientific Inc. offer end-to-end suites that integrate trial design, PBPK modeling, and data analytics. Certara, Inc., Schrodinger, Inc., and Simulations Plus, Inc. continue to expand through strategic acquisitions, broadening their service offerings and enhancing platform interoperability. CRO-aligned consultancies such as BioSimulation Consulting Inc. and Quotient Sciences Limited deliver hybrid models combining software tools with deep domain experience. Emerging players including Model Vitals, VIRTUALMAN, and VeriSIM Life are advancing digital twin technologies, while companies like Cell Works Group, Cytel Inc., and INOSIM Software GmbH target specialized segments from cell-based models to process simulations. Collectively, this roster of over two dozen organizations drives continuous innovation, partnering to co-develop solutions, coalesce around regulatory guidance, and foster best practices that elevate the entire biosimulation ecosystem.

Actionable Recommendations for Industry Leaders

Industry leaders should adopt a multi-pronged approach that balances technology investment with strategic partnerships. First, integrating modular software platforms that support molecular modeling, PBPK, PK/PD, and trial design will ensure seamless data flow and reduce manual handoffs. Second, embracing subscription-based delivery models can optimize capital allocation and enable rapid scaling of simulation workloads in response to project demands. Third, cultivating alliances with contract research organizations and academic centers provides access to specialized expertise and shared computing resources, accelerating project timelines. Fourth, actively engaging with regulatory authorities through pilot programs and validation studies will clarify submission pathways for model-informed drug development, de-risking regulatory reviews. Fifth, expanding capabilities in emerging markets-particularly within Asia-Pacific hubs-can tap into cost-effective talent pools and benefit from government incentives. Sixth, investing in workforce upskilling and cross-disciplinary training ensures teams stay proficient with evolving algorithms, cloud architectures, and data-integration best practices. By implementing these targeted actions, organizations can enhance agility, manage regulatory complexity, and sustain competitive differentiation as biosimulation becomes integral to their R&D strategies.

Conclusion: Capturing the Full Potential of Biosimulation

Biosimulation has matured into a strategic enabler that drives efficiency, mitigates risk, and informs critical development decisions. From transformative shifts in computational capabilities to the real-world ramifications of tariff policies, the landscape demands proactive adaptation. Segmentation analysis underscores the importance of offering flexibility across services, software, delivery models, and end-user needs. Regional variations highlight where growth can be unlocked through aligned regulatory strategies and localized partnerships. Competitive insights reveal a dynamic ecosystem in which collaboration accelerates innovation. By following targeted recommendations-from adopting integrated platforms to engaging regulators-organizations can harness the full power of biosimulation. Embracing this paradigm not only supports expedited timelines and cost containment but also enhances the scientific rigor underlying therapeutic advancements. As the biosimulation field continues to evolve, those who act decisively will shape the next frontier of drug discovery and development.

Market Segmentation & Coverage

This research report categorizes the Biosimulation Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Services
    • Contract Services
    • In-House Services
  • Software
    • Molecular Modeling & Simulation Software
    • PBPK Modeling & Simulation Software
    • PK/PD Modeling & Simulation Software
    • Toxicity Prediction Software
    • Trial Design Software
  • Ownership Models
  • Subscription Models
  • Drug Development
    • Clinical Trials
    • Preclinical Testing
      • ADME/Tox
      • PK/PD
  • Drug Discovery
    • Lead Identification & Optimization
    • Target Identification & Validation
  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies
  • Regulatory Authorities
  • Research Institutes

This research report categorizes the Biosimulation Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • Massachusetts
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Biosimulation Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Advanced Chemistry Development, Inc.
  • Aitia
  • Allucent
  • Biomed Simulation, Inc.
  • BioSimulation Consulting Inc.
  • Cadence Design Systems, Inc.
  • Cell Works Group, Inc.
  • Certara, Inc.
  • Chemical Computing Group ULC
  • Crystal Pharmatech Co., Ltd.
  • Cytel Inc.
  • Dassault Systèmes SE
  • ICON PLC
  • In Silico Biosciences, Inc.
  • INOSIM Software GmbH
  • Instem PLC
  • Model Vitals
  • Physiomics PLC
  • Quotient Sciences Limited
  • Resolution Medical
  • Schrodinger, Inc.
  • Simulations Plus, Inc.
  • Thermo Fisher Scientific Inc.
  • VeriSIM Life
  • VIRTUALMAN
  • Yokogawa Electric Corporation

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biosimulation Market, by Offering
8.1. Introduction
8.2. Services
8.2.1. Contract Services
8.2.2. In-House Services
8.3. Software
8.3.1. Molecular Modeling & Simulation Software
8.3.2. PBPK Modeling & Simulation Software
8.3.3. PK/PD Modeling & Simulation Software
8.3.4. Toxicity Prediction Software
8.3.5. Trial Design Software
9. Biosimulation Market, by Delivery Model
9.1. Introduction
9.2. Ownership Models
9.3. Subscription Models
10. Biosimulation Market, by Application
10.1. Introduction
10.2. Drug Development
10.2.1. Clinical Trials
10.2.2. Preclinical Testing
10.2.2.1. ADME/Tox
10.2.2.2. PK/PD
10.3. Drug Discovery
10.3.1. Lead Identification & Optimization
10.3.2. Target Identification & Validation
11. Biosimulation Market, by End-User
11.1. Introduction
11.2. Contract Research Organizations
11.3. Pharmaceutical & Biotechnology Companies
11.4. Regulatory Authorities
11.5. Research Institutes
12. Americas Biosimulation Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Biosimulation Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Biosimulation Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Advanced Chemistry Development, Inc.
15.3.2. Aitia
15.3.3. Allucent
15.3.4. Biomed Simulation, Inc.
15.3.5. BioSimulation Consulting Inc.
15.3.6. Cadence Design Systems, Inc.
15.3.7. Cell Works Group, Inc.
15.3.8. Certara, Inc.
15.3.9. Chemical Computing Group ULC
15.3.10. Crystal Pharmatech Co., Ltd.
15.3.11. Cytel Inc.
15.3.12. Dassault Systèmes SE
15.3.13. ICON PLC
15.3.14. In Silico Biosciences, Inc.
15.3.15. INOSIM Software GmbH
15.3.16. Instem PLC
15.3.17. Model Vitals
15.3.18. Physiomics PLC
15.3.19. Quotient Sciences Limited
15.3.20. Resolution Medical
15.3.21. Schrodinger, Inc.
15.3.22. Simulations Plus, Inc.
15.3.23. Thermo Fisher Scientific Inc.
15.3.24. VeriSIM Life
15.3.25. VIRTUALMAN
15.3.26. Yokogawa Electric Corporation
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BIOSIMULATION MARKET MULTI-CURRENCY
FIGURE 2. BIOSIMULATION MARKET MULTI-LANGUAGE
FIGURE 3. BIOSIMULATION MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BIOSIMULATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BIOSIMULATION MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOSIMULATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY IN-HOUSE SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY MOLECULAR MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY PBPK MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOSIMULATION MARKET SIZE, BY TOXICITY PREDICTION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOSIMULATION MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOSIMULATION MARKET SIZE, BY OWNERSHIP MODELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOSIMULATION MARKET SIZE, BY SUBSCRIPTION MODELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOSIMULATION MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOSIMULATION MARKET SIZE, BY ADME/TOX, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOSIMULATION MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOSIMULATION MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOSIMULATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOSIMULATION MARKET SIZE, BY REGULATORY AUTHORITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOSIMULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. CANADA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 67. CANADA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 68. CANADA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 69. CANADA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 70. CANADA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 72. CANADA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 73. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 74. CANADA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. MEXICO BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 76. MEXICO BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 77. MEXICO BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 78. MEXICO BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 79. MEXICO BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 81. MEXICO BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 82. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 83. MEXICO BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 102. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 104. AUSTRALIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 106. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 107. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 108. AUSTRALIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 111. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 112. AUSTRALIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. CHINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 114. CHINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 115. CHINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 116. CHINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 117. CHINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 119. CHINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 120. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 121. CHINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. INDIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 123. INDIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 124. INDIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 125. INDIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 126. INDIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 128. INDIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 129. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 130. INDIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. INDONESIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 132. INDONESIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 133. INDONESIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 134. INDONESIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 135. INDONESIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 138. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 139. INDONESIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. JAPAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 141. JAPAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 142. JAPAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 143. JAPAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 144. JAPAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 146. JAPAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 147. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 148. JAPAN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 149. MALAYSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 150. MALAYSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 151. MALAYSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 152. MALAYSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 153. MALAYSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 155. MALAYSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 156. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 157. MALAYSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. PHILIPPINES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 159. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 160. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 161. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 162. PHILIPPINES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 164. PHILIPPINES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 165. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 166. PHILIPPINES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 167. SINGAPORE BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 168. SINGAPORE BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 169. SINGAPORE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 170. SINGAPORE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 171. SINGAPORE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 173. SINGAPORE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 174. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 175. SINGAPORE BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 177. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 178. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 179. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 180. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 182. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 183. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 184. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. TAIWAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 186. TAIWAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 187. TAIWAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 188. TAIWAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 189. TAIWAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. TAIWAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 191. TAIWAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 192. TAIWAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 193. TAIWAN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. THAILAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 195. THAILAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 196. THAILAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 197. THAILAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 198. THAILAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. THAILAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 200. THAILAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 201. THAILAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 202. THAILAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. VIETNAM BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 204. VIETNAM BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 205. VIETNAM BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 206. VIETNAM BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 207. VIETNAM BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. VIETNAM BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 209. VIETNAM BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 210. VIETNAM BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 211. VIETNAM BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 222. DENMARK BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 223. DENMARK BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 224. DENMARK BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 225. DENMARK BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 226. DENMARK BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 227. DENMARK BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 228. DENMARK BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 229. DENMARK BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 230. DENMARK BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 231. EGYPT BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 232. EGYPT BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 233. EGYPT BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 234. EGYPT BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 235. EGYPT BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. EGYPT BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 237. EGYPT BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 238. EGYPT BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 239. EGYPT BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 240. FINLAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 241. FINLAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 242. FINLAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 243. FINLAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 244. FINLAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. FINLAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 246. FINLAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 247. FINLAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 248. FINLAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 249. FRANCE BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 250. FRANCE BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 251. FRANCE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 252. FRANCE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 253. FRANCE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. FRANCE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 255. FRANCE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 256. FRANCE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 257. FRANCE BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 258. GERMANY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 259. GERMANY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 260. GERMANY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 261. GERMANY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 262. GERMANY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. GERMANY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 264. GERMANY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 265. GERMANY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 266. GERMANY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 274. ISRAEL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 275. ISRAEL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 276. ITALY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 277. ITALY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 278. ITALY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 279. ITALY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 280. ITALY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 281. ITALY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 282. ITALY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 283. ITALY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 284. ITALY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 294. NIGERIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 295. NIGERIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 296. NIGERIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 297. NIGERIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 298. NIGERIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 299. NIGERIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 300. NIGERIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 301. NIGERIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 302. NIGERIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 303. NORWAY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 304. NORWAY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 305. NORWAY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 306. NORWAY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 307. NORWAY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 308. NORWAY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 309. NORWAY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 310. NORWAY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 311. NORWAY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 312. POLAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 313. POLAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 314. POLAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 315. POLAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 316. POLAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 317. POLAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 318. POLAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 319. POLAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 320. POLAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 321. QATAR BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 322. QATAR BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 323. QATAR BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 324. QATAR BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 325. QATAR BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 326. QATAR BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 327. QATAR BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 328. QATAR BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 329. QATAR BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 330. RUSSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 331. RUSSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 332. RUSSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 333. RUSSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 334. RUSSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 335. RUSSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 336. RUSSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 337. RUSSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 338. RUSSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 339. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 340. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 341. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 342. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 343. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 344. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 345. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 346. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 347. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 348. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 349. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 350. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 351. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 352. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 353. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 354. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 355. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 356. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 357. SPAIN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 358. SPAIN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 359. SPAIN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 360. SPAIN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 361. SPAIN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 362. SPAIN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 363. SPAIN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
TABLE 364. SPAIN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 365. SPAIN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 366. SWEDEN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 367. SWEDEN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 368. SWEDEN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
TABLE 369. SWEDEN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
TABLE 370. SWEDEN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 371. SWEDEN BIOSIMULATI

Companies Mentioned

  • Advanced Chemistry Development, Inc.
  • Aitia
  • Allucent
  • Biomed Simulation, Inc.
  • BioSimulation Consulting Inc.
  • Cadence Design Systems, Inc.
  • Cell Works Group, Inc.
  • Certara, Inc.
  • Chemical Computing Group ULC
  • Crystal Pharmatech Co., Ltd.
  • Cytel Inc.
  • Dassault Systèmes SE
  • ICON PLC
  • In Silico Biosciences, Inc.
  • INOSIM Software GmbH
  • Instem PLC
  • Model Vitals
  • Physiomics PLC
  • Quotient Sciences Limited
  • Resolution Medical
  • Schrodinger, Inc.
  • Simulations Plus, Inc.
  • Thermo Fisher Scientific Inc.
  • VeriSIM Life
  • VIRTUALMAN
  • Yokogawa Electric Corporation

Methodology

Loading
LOADING...

Related Topics

Related Reports

Biosimulation Market Size, Share & Trends Analysis Report By Product (Software, Services), By Application, Therapeutic Area, By Deployment Model, By Pricing Model, By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biosimulation Market Size, Share & Trends Analysis Report By Product (Software, Services), By Application, Therapeutic Area, By Deployment Model, By Pricing Model, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Biosimulation Market by Offering (Module, Integrated Platform), Application (Disease Modeling, PBPK, PKPD, Trial Simulation, Manufacturing & Supply Chain: Planning & Forecasting), Indication (Cancer, CNS, CVS), End User, & Region - Global Forecast to 2029 - Product Image

Biosimulation Market by Offering (Module, Integrated Platform), Application (Disease Modeling, PBPK, PKPD, Trial Simulation, Manufacturing & Supply Chain: Planning & Forecasting), Indication (Cancer, CNS, CVS), End User, & Region - Global Forecast to 2029

  • Report
  • 386 Pages
  • Global
From
Biosimulation Market (2024 Edition): Analysis By Type (Services, Software), By Application, By Deployment Model Outlook, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Biosimulation Market (2024 Edition): Analysis By Type (Services, Software), By Application, By Deployment Model Outlook, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 241 Pages
  • Global
From
Biosimulation Technology - Global Strategic Business Report - Product Image

Biosimulation Technology - Global Strategic Business Report

  • Report
  • 214 Pages
  • Global
From

About the Biosimulation Market

The Biosimulation market is a subset of the biotechnology industry that focuses on the development of computer-based models to simulate biological processes. These models are used to study the behavior of biological systems, such as the interactions between cells, organs, and organisms. Biosimulation can be used to predict the effects of drugs, understand the mechanisms of disease, and develop new treatments. It can also be used to optimize the production of biopharmaceuticals and to design new bioprocesses. Biosimulation is a rapidly growing field, with many companies investing in the development of new technologies and applications. Companies in the market include Certara, Entelos, Simulations Plus, Schrodinger, and In Silico Biosciences. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.